Your browser doesn't support javascript.
loading
A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen.
Du, Yikuan; Guo, Zhuoming; Xu, Bijun; Yang, Yujia; Hu, Mianda; Hu, Yanghui; Yang, Yurong; Zhang, Mengting; Wang, Zhenjie; Guo, Xiaochun; Huang, Yixing; Zhu, Jinfeng; Zhang, Weichui; Yang, Chun.
Afiliación
  • Du Y; Central Laboratory, The Tenth Affiliated Hospital of Southern Medical University, Dongguan, China.
  • Guo Z; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Xu B; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Yang Y; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Hu M; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Hu Y; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Yang Y; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Zhang M; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Wang Z; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Guo X; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Huang Y; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Zhu J; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Zhang W; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
  • Yang C; Dongguan Key Laboratory of Chronic lnflammatory Diseases, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, China.
Expert Opin Drug Saf ; : 1-11, 2024 May 09.
Article en En | MEDLINE | ID: mdl-38686498
ABSTRACT

INTRODUCTION:

Ibuprofen is commonly used as an over-the-counter (OTC) antipyretic and analgesic. As the frequency of its use has increased, there has been a corresponding increase in reports of associated adverse events (AEs). However, these events have not been systematically reported in the literature. Meanwhile, the importance of effective pharmacovigilance in evaluating the benefits and risks of drugs is being recognized.

METHODS:

The data was obtained indirectly from FAERS using the OpenVigil 2 database, lexically mapped using software such as MySQL, Microsoft Excel, and the R language, and then subjected to four more rigorous algorithms to detect risk signals associated with ibuprofen AEs.

RESULTS:

By analyzing data from the past 18 years, 878 ibuprofen-related AEs were identified as primary AEs. Notably, unexpected reproductive system and breast diseases, etc., which were unexpected, were observed as important system organ classes (SOCs) associated with ibuprofen. Among the 651 preferred terms (PTs) that simultaneously satisfy the four arithmetic methods, renal tubular acidosis and lip oedema are proposed as new signals for ibuprofen AEs.

CONCLUSION:

This study explores the important and valuable potential AEs and ADRs of ibuprofen at the SOC and PT levels, respectively. To provide a reference on decision-making for ibuprofen to promote rational clinical dosing.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: China